Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19
antiviral treatments, but their antiviral activities in patients have not been compared …

Background Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …

Background: There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …

Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …

Background Effective antiviral drugs prevent hospitalisation and death from COVID-19.
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …

Background Uncertainty over the therapeutic benefit provided by parenteral remdesivir in
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …

The Portuguese Severe Asthma Registry (Registo de Asma Grave Portugal, RAG) was
developed by an open collaborative network of asthma specialists. RAG collects data from adults …

Background There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment …

Background Proper evaluation of therapeutic responses in Chagas disease is hampered by
the prolonged persistence of antibodies to Trypanosoma cruzi measured by conventional …

Background The COVID-19 pandemic affected all WHO member states. We compared and
contrasted the COVID-19 treatment guidelines of each member state with the WHO COVID-…